Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Recent Press Releases
More >>
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Investor Downloads

Download Documentation AP26113 Phase 1/2 Update – ESMO 2014
Download Documentation Ponatinib Phase 2 GIST Trial – ESMO 2014
Download Documentation Corporate Presentation
More >>

ARIAD Stock Price: $5.28

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 10/01/14

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Down 0.12 (2.22%)
DAY LOW$5.19
52 WK. HIGH$19.18
Minimum 20 minute delay
Refresh quote
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

You are now leaving this website. If you would like to continue, click Continue.